• Shattuck Labs named Shoba Ravichandran as senior vice president, clinical development to lead the SL-325 hidradenitis suppurativa program.
• Ravichandran previously spent more than a decade at Novartis, most recently as senior global program clinical head.
• She led the global approval of Cosentyx in hidradenitis suppurativa, also led Phase 3 start-up for remibrutinib in the disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837550) on October 01, 2026, and is solely responsible for the information contained therein.